
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
🔬 Science
💰 $85M Series B on 2022-01
October 29
Medical Writing Operations Manager driving operational excellence and consistency in regulatory submissions for biopharmaceutical company. Responsible for document coordination and quality control.
🇺🇸 United States – Remote
💵 $70 - $80 / hour
💰 $85M Series B on 2022-01
⏳ Contract/Temporary
🟠 Senior
🔴 Lead
✏️ Content Writer